Edwards Lifesciences Corp Stock Price, News & Analysis

Edwards Lifesciences (NYSE: EW) has announced its decision to acquire Innovalve Bio Medical , an early-stage transcatheter mitral valve replacement (TMVR) company. This move follows Edwards' initial investment in Innovalve in 2017 and is based on the company's promising early clinical experience. The acquisition aims to enhance Edwards' TMVR technologies, addressing unmet structural heart patient needs and supporting long-term growth.

Innovalve will join Edwards' transcatheter mitral and tricuspid therapies (TMTT) product group. The company's SAPIEN M3 is expected to become the first approved transfemoral TMVR system in Europe by the end of 2025. Edwards believes that combining Innovalve's technologies with its own mitral expertise will expand the treatable population for TMVR. The acquisition is set to close by the end of 2024.

Edwards Lifesciences (NYSE: EW) has released five-year data from the PARTNER Trials, showcasing excellent outcomes for patients, particularly women and those with a small annulus, undergoing transcatheter aortic valve replacement (TAVR) using the SAPIEN 3 valve.

The analysis included over 1,300 low and intermediate risk patients and demonstrated favorable clinical outcomes and valve durability regardless of annulus size or sex. Key findings include no link between higher 30-day mean gradients or severe prosthesis-patient mismatch (PPM) with poor long-term outcomes.

Presented at New York Valves 2024, the data highlighted low reintervention rates and high five-year survival rates, reinforcing the reliability of the SAPIEN 3 valve platform for diverse patient groups.

Edwards Lifesciences announced the sale of its Critical Care product group to BD (Becton, Dickinson and Company) for $4.2 billion in cash. The transaction will enhance Edwards' financial flexibility and enable strategic investments in structural heart disease technologies. The deal is expected to close by the end of 2024, pending regulatory approvals. Edwards aims to focus on advancing innovations in aortic, mitral, tricuspid, and pulmonic treatments. The sale is anticipated to have an immaterial impact on adjusted EPS in 2024.

BD (Becton, Dickinson and Company) has announced an agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition aims to expand BD's portfolio of smart connected care solutions and enhance its position in advanced monitoring technologies.

Critical Care, a global leader in advanced patient monitoring, generated over $900 million in revenue in 2023 and employs approximately 4,500 people. The acquisition is expected to be immediately accretive to BD's revenue growth, adjusted gross and operating margins, and adjusted earnings per share.

Critical Care will operate as a separate business unit within BD's Medical segment and will continue to be based in Irvine, California, under the leadership of Katie Szyman. The transaction is expected to close by the end of the calendar year, subject to regulatory reviews and closing conditions.

BD plans to fund the acquisition with a combination of $1 billion in cash and $3.2 billion in new debt. The company expects to achieve additional margin expansion and value through cost synergies and efficiencies.

Edwards Lifesciences has launched the SAPIEN 3 Ultra RESILIA valve in Europe, incorporating breakthrough RESILIA tissue technology for enhanced durability. The valve received CE Mark for patients with heart valve disease, with RESILIA tissue offering potential for extended durability. The valve aims to improve quality of life and future treatment options with lower rates of paravalvular leak and larger effective orifice areas. The technology is backed by 7-year COMMENCE Study data showing excellent outcomes. RESILIA tissue is a result of 20 years of research, indicating Edwards' focus on patient-centric technology.